Press release
ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief to Present at Keystone Cancer Vaccines Conference
The talk titled "Therapeutic HPV16 Vaccination Is Effective as Monotherapy in Pre-Malignant Disease, but Requires Combination Treatment in HPV16-Induced Cancers" is scheduled for Thursday, January 24, 2019, at 17:00 as part of the session "Immune Monitoring of T Cells" (17:00-18-45, Pacific Ballroom).
The data will outline the T cell response to ISA Pharmaceuticals´ therapeutic vaccine ISA101 and the resulting clinical activity. ISA101 is directed against the HPV16 oncoproteins E6/E7 and is the Company´s clinical-stage lead compound. It is being developed to treat HPV16-induced cancers such as cervical cancer and head-and-neck cancer.
###
About ISA Pharmaceuticals
ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT® technology. SLP® immunotherapies are designed to fully harness and direct the body’s own defenses towards fighting the disease. In December 2017, ISA Pharmaceuticals closed a clinical immuno-oncology collaboration with Regeneron to advance its SLP® lead compound ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer, in combination with Cemiplimab (REGN2810), a PD-1 (programmed cell death protein 1) antibody. In addition, ISA develops SLP® immunotherapies to advance novel treatment options for orphan indications.
For more information, please visit www.isa-pharma.com.
SLP® and AMPLIVANT® are registered trademarks in Europe.
Miranda Molenaar
ISA Pharmaceuticals B.V.
J.H. Oortweg 19
NL-2333 CH Leiden
The Netherlands
T: +31 71 33 22 310
F: +31 71 33 22 311
E: info@isa-pharma.com
Contact & Media Inquiries:
akampion
Dr. Ludger Wess, Ines-Regina Buth
Managing Partners
Tel. +49 40 88 16 59 64, +49 30 23 63 27 68
info(at)akampion.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief to Present at Keystone Cancer Vaccines Conference here
News-ID: 1502313 • Views: …
More Releases from ISA Pharmaceuticals
ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeti …
- Results from Phase 2 cervical cancer trial with ISA101 selected for plenary oral presentation
Leiden, The Netherlands, March 28, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis Melief will give an oral presentation at the upcoming AACR Annual Meeting 2019 in Atlanta, GA, USA, on March 31, 2019.
The presentation titled "A strong HPV-specific T-cell response after chemo-immunotherapy for advanced…
ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Cornelis Melief Receiv …
- Recognition for outstanding and innovative cancer research
Leiden, The Netherlands, March 19, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis Melief will receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019 from the American Association of Cancer Research (AACR) and the Cancer Research Institute.
The AACR-CRI Lloyd J. Old Award in Cancer Immunology recognizes an active…
ISA Pharmaceuticals Announces Start of Phase 2 Combination Trial of ISA101b and …
- ISA101b and Cemiplimab studied in patients with platinum refractory HPV16-positive oropharyngeal cancer (OPC)
Leiden, The Netherlands, January 21, 2019 – ISA Pharmaceuticals B.V., a clinical-stage company dedicated to the development of rationally designed immunotherapeutics, today announced randomization of the first patient in a Phase 2 combination trial of its lead compound ISA101b and Regeneron´s (NASDAQ: REGN) anti-PD-1 antibody cemiplimab (REGN2810).
This double blind, placebo-controlled, randomized, phase 2 study (NCT03669718)…
ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief Receives ES …
Leiden, The Netherlands, November 13, 2018 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Cornelis Melief has been selected by the European Society for Medical Oncology (ESMO) to receive the 2018 ESMO Immuno-Oncology Award in recognition of his life’s work in studying the interactions of the immune system with cancer. He will receive the award during an official ceremony at the opening…
More Releases for HPV16
Human Papillomavirus 16-positive (HPV16+) Cancer Market to Witness Unstoppable G …
Human papillomavirus (HPV) is the most common sexually transmitted infection, with a high probability of infection with the virus for both males and females across their lifetime.
Although the immune system eliminates most HPV infections without complications, some HPV-induced growths can progress to cancer. HPV 16 is the subtype found in most cancers and accounts for most cases of cervix, vagina, anus, and oropharynx cancers.
Despite advances in the understanding of…
Gardasil (HPV Vaccine) Market Industry Analysis, Growth, Trends and Forecast 202 …
HPV is a group of viruses, the composition of a family, the virus morphology is similar, but the DNA restriction enzyme map is different, the nucleocapsid protein antigenicity is different.At present, there are about 100 types of HPV identified, which are divided into cutaneous HPV and genital epithelial HPV according to the location of the infected epithelium. About 35 types can infect the female genital tract, and about 20 types…
ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeti …
- Results from Phase 2 cervical cancer trial with ISA101 selected for plenary oral presentation
Leiden, The Netherlands, March 28, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis Melief will give an oral presentation at the upcoming AACR Annual Meeting 2019 in Atlanta, GA, USA, on March 31, 2019.
The presentation titled "A strong HPV-specific T-cell response after chemo-immunotherapy for advanced…
ISA Pharmaceuticals Announces Start of Phase 2 Combination Trial of ISA101b and …
- ISA101b and Cemiplimab studied in patients with platinum refractory HPV16-positive oropharyngeal cancer (OPC)
Leiden, The Netherlands, January 21, 2019 – ISA Pharmaceuticals B.V., a clinical-stage company dedicated to the development of rationally designed immunotherapeutics, today announced randomization of the first patient in a Phase 2 combination trial of its lead compound ISA101b and Regeneron´s (NASDAQ: REGN) anti-PD-1 antibody cemiplimab (REGN2810).
This double blind, placebo-controlled, randomized, phase 2 study (NCT03669718)…
Global Cervical Cancer Vaccine Market Application Segment Analysis (Consumption …
Overview for Global Cervical Cancer Vaccine Market Helps in providing scope and definations, Key Findings, Growth Drivers, and Various Dynamics.
Description:
The Global Cervical Cancer Vaccine Market report for the forecast period of 2017 – 2023 by MI Reports is a key insight into the Cervical Cancer Vaccine across various parameters. The solid research on the Cervical Cancer Vaccine is prepared with the aim to meet the requirements of the customer in…
ISA Pharmaceuticals' ISA101 Studied in Phase II Oropharyngeal Cancer Combination …
Leiden, The Netherlands, April 26, 2018 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the start of a Phase II combination trial of its lead compound ISA101b and Pfizer´s 4-1BB agonist Utomilumab, which will be sponsored and conducted by The University of Texas MD Anderson Cancer Center (Houston, TX).
The goal of the open-label Phase II study in…
